Novartis collaborates with Molecular Partners to develop two DARPin therapies designed for Covid-19

This article was originally published here

The collaboration aims to leverage Molecular Partners’ proprietary DARPin technologies and Novartis broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to rapidly advance the program

The post Novartis collaborates with Molecular Partners to develop two DARPin therapies designed for Covid-19 appeared first on Pharmaceutical Business review.